Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurora CannabisACB +0.40%61 Cash-to-Debt is 4.41 as of Jun. 2026, which is 308% above its 10-year median of 1.08. GuruFocus rates ACB with a GF Score™ of 61/100 and a GF Value™ of $3.78 (Fairly Valued). The stock has 2 warning signs investors should review. Among 985 Drug Manufacturers companies, Aurora Cannabis ranks better than 69.54% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Aurora Cannabis's cash to debt ratio for the quarter that ended in Jun. 2026 was 4.41.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Aurora Cannabiscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Aurora Cannabis's Cash-to-Debt or its related term are showing as below:
ACB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.24 Med: 1.08 Max: 1350.63
Current: 4.41
During the past 13 years, Aurora Cannabis's highest Cash to Debt Ratio was 1350.63. The lowest was 0.24. And the median was 1.08.
ACB's Cash-to-Debt is ranked better than 69.54% of 985
companies
in the Drug Manufacturers industry
Industry Median: 0.96
vs ACB: 4.41
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Aurora Cannabis Cash-to-Debt Related Terms
Aurora Cannabis Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Aurora Cannabis's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Aurora Cannabis's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurora Cannabis Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aurora Cannabis's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Aurora Cannabis's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurora Cannabis (ACB) has a Cash-to-Debt of 4.41 as of Jun. 2026. This is 308% above median its historical median of 1.08. Over the past decade, Aurora Cannabis' Cash-to-Debt has ranged from 0.24 to 1,350.63. According to the industry distribution chart, Aurora Cannabis ranks #300 out of 985 companies in the Drug Manufacturers industry, placing it in the top 30.5%.
Is Aurora Cannabis' Cash-to-Debt too high?
Aurora Cannabis' current Cash-to-Debt of 4.41 is 308% above median its 10-year median of 1.08. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 1,350.63. The Drug Manufacturers industry median Cash-to-Debt is 0.96. Aurora Cannabis' value of 4.41 is 359.4% above this industry median. Based on the distribution chart, Aurora Cannabis ranks #300 out of 985 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aurora Cannabis has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aurora Cannabis' Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Aurora Cannabis ranks #300 out of 985 companies for Cash-to-Debt. This puts Aurora Cannabis in the upper half of its industry. The industry median Cash-to-Debt is 0.96. Aurora Cannabis' value of 4.41 is 359.4% above this benchmark. Historically, Aurora Cannabis' own Cash-to-Debt has ranged from 0.24 to 1,350.63 over the past decade. While the company's 10-year median is 1.08 vs. the industry median of 0.96, Aurora Cannabis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.96, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurora Cannabis's current Cash-to-Debt of 4.41 is 359.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurora Cannabis's current Cash-to-Debt is 4.41, which is 308% above median its own 10-year median of 1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurora Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Aurora Cannabis (ACB) is currently considered Fairly Valued. The stock's GF Value™ is $3.78, compared to a current price of $3.74 — trading 1.1% below its estimated fair value. The current Cash-to-Debt is 4.41, which is 308% above median its 10-year median of 1.08 and 359.4% above the Drug Manufacturers industry median of 0.96. Aurora Cannabis' overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Aurora Cannabis (ACB), the current Cash-to-Debt is 4.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurora Cannabis (ACB) Overvalued in 2026?
Based on GuruFocus' analysis, Aurora Cannabis stock appears to be undervalued.
The current stock price of $3.74 is trading 1.1% below its estimated GF Value™ of $3.78.
GuruFocus considers Aurora Cannabis to be Fairly Valued.
Key valuation signals for ACB:
Cash-to-Debt: 4.41 (308% above median its 10-year median of 1.08)
GF Value™: $3.78 vs. price of $3.74 (1.1% below fair value)
Industry Position: 359.4% above the Drug Manufacturers median (#300 of 985)
No single metric tells the full story. See the ACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.
61GF Score
Get the complete analysis for ACB
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACB has been successfully added to your 
